This recent article in the Sunday Times discusses how an extract of magic mushrooms may be able to make significant improvements in the treatment of severe depression.

We were delighted to bring ApconiX’s drug project toxicologist expertise to the team of experts working with COMPASS Pathways to find a safe, efficient and effective route into clinical trials. 

The 400-patient trial will establish whether psilocybin, the active ingredient in magic mushrooms, can help patients where other treatments have failed.

COMPASS Pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. We are proud to support them in this mission.   

 

By |2019-06-06T14:49:45+01:00February 13th, 2018|Toxicology|Comments Off on Magic Mushrooms May Treat Depression

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath. A co-founder of ApconiX, Ruth has 25 years of experience in leading roles in drug safety within large pharma. Ruth is also Chair and Director of Drug Discovery at The University of Birmingham, UK and was previously Global Head of Regulatory Safety at AstraZeneca. With over 140 publications in peer-reviewed journals, she is former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and President of the Academy of Toxicological Sciences. Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development.